Research article

                    Mitochondrial complex activity                        NAD+/NADH balance regulate
                         breast cancer progression
              Antonio F. Santidrian,1,2 Akemi Matsuno-Yagi,1 Melissa Ritland,1,2 Byoung B. Seo,1
            Sarah E. LeBoeuf,1,2 Laurie J. Gay,1,2 Takao Yagi,1 Brunhilde Felding-Habermann1,2
   1Department    Molecular Experimental Medicine 2Department Chemical Physiology, Scripps Research Institute, La Jolla, California, USA.


    Despite advances clinical therapy, metastasis remains leading cause death breast cancer patients.
    Mutations mitochondrial DNA, including affecting complex oxidative phosphorylation,     breast tumors facilitate metastasis. study identifies mitochondrial complex     critical defining aggressive phenotype breast cancer cells. Specific enhancement mitochondrial
    complex activity inhibited tumor growth metastasis regulation tumor cell NAD+/NADH
    redox balance, mTORC1 activity, autophagy. Conversely, nonlethal reduction NAD + levels inter-
    fering nicotinamide phosphoribosyltransferase expression rendered tumor cells aggressive     increased metastasis. results translate new therapeutic strategy: enhancement NAD+/NADH
    balance treatment NAD+ precursors inhibited metastasis xenograft models, increased animal
    survival, strongly interfered oncogene-driven breast cancer progression MMTV-PyMT mouse
    model.  aberration mitochondrial complex NADH dehydrogenase activity profoundly enhance
    aggressiveness human breast cancer cells, therapeutic normalization NAD +/NADH balance
    inhibit metastasis prevent disease progression.

Introduction                                                                             noncoding D-loop region (9, 10), mitochondrial complex Despite advances clinical therapy, metastasis lead-                      subunit genes (10). defects suggest role mtDNA muta-
ing cause death breast cancer patients (1). clearer                        tions complex tumor progression.  cell
standing molecular mechanisms drive metastasis                              lines excellent models defining specific role complex help develop effective therapies (2). present study                          activity tumor growth metastatic aggressiveness.
focused metabolism essential driver tumor growth                                Complex gatekeeper respiratory chain catalyz- metastasis, potentially common breast cancer types.                           es step NADH oxidation. elevates NAD+/NADH
Normal cells primarily use mitochondrial oxidative phosphory-                            ratio translocates protons inner mitochondrial
lation (OXPHOS) energy production, cancer cells                              membrane, ultimately leads energy production. mtDNA
depend aerobic glycolysis  Warburg effect) generate                            mutations genes encoding complex subunits energy glycolytic intermediates enhanced growth (3, 4).                          malignancies including breast cancer (6, 11â€“14, 16).  Tumor cells generate high levels reduced forms NAD+,                          largely unknown alterations complex cellular
NADH, NADPH important cofactors redox compo-                                  NAD+/NADH redox balance affect tumorigenesis metastasis.
nents (4, 5). altered metabolic activities linked                           used unique approach define contributions com-
mitochondrial dysfunction inhibits OXPHOS, increases                                plex activity breast cancer progression, based expression
ROS, promotes uncontrolled growth, causes DNA damage                                 yeast NADH dehydrogenase Ndi1 human tumor cells. supports metastatic phenotype (6, 7). Mitochon-                           Ndi1 encodes single protein faces inner mitochondrial
drial dysfunctions caused mutations mitochondrial                           matrix oxidizes NADH Krebs cycle. Unlike mamma-
DNA (mtDNA) nuclear genes encoding mitochondrial pro-                                 lian complex  Ndi1 rotenone insensitive (17). Ndi1 contains 26
teins (6, 8) essential respiratory chain/OXPHOS                         N-terminal residues mitochondrial import (17), func-  lack protective histones limited DNA                           tionally expressed mammalian cells (18, 19), does cause
repair (8), mtDNA mutations occur high rates                           immune response (20). Ndi1 restores complex function (18) tumors including breast cancer (6, 9â€“14), suggests                         diseased cells, e.g., neurons Parkinsonâ€™s disease (21) optic
defects OXPHOS contribute tumorigenesis.                                     neuropathy (22); protects cardiomyocytes ischemic reperfu-
  combining nuclear genome recipient cell                           sion injury (23); increases lifespan Drosophila (24). Recently,
mitochondrial genome donor cell using cybrid technology,                            shown Ndi1 expression complex deficient tumor
mitochondria triple-negative aggressive breast cancer                           cells reduce soft agar colony formation (25).
cell lines MDA-MB-435 (15) MDA-MB-231 facilitated tumor                                 used Ndi1 investigate cause effect relationship
progression metastasis nonmetastatic tumor cells (7, 10).                         aberrant mitochondrial complex activity malig- donor cell lines harbor mtDNA mutations tRNAs,                             nant progression breast cancer.  analyzed meta-
                                                                                         bolic alterations caused mitochondrial complex malfunction
Conflict  authors declared conflict exists.     translated information gained novel therapeutic
Citation article: J Clin Invest. 2013;123(3):1068â€“1081. doi:10.1172/JCI64264.   approach breast cancer progression.

1068	                                 Journal Clinical Investigationâ€‚â€‚â€‚ http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013
                                                                                                                                  research article




Figure 1
Enhancement mitochondrial complex activity integration Ndi1: metabolic characterization.   Ndi1 expressed MDA-MB-435 MDA-MB-231 human cancer cells lentiviral transduction localized mitochondria, shown dual label immunocytochemistry. Control
cells (Ctrl) transduced vector. Shown Ndi1 (green), mitochondrial complex V (red), merged (yellow) staining patterns representative fields. Original magnification, Ã—20. (B) Ndi1 integrated mitochondrial respiratory chain enhanced tumor
cell respiration. Respiration MDA-MB-435 MDA-MB-231 (denoted â€œ435â€? â€œ231,â€? respectively) control Ndi1-expressing cells, mea-
sured oxygen consumption. R, routine respiration; Rot, rotenone (mammalian complex inhibitor); AA, antimycin (complex III inhibitor). parameters measured high-resolution respirometry intact cells. (C) Effects Ndi1 expression cellular metabolism MDA-MB-435 MDA-MB-231 cells. mtDNA content analyzed quantitative real-time PCR referenced nuclear genomic DNA. Mitochondrial mem-
brane potential analyzed flow cytometry expressed geometric mean signal. ATP levels measured ATP-dependent
luciferase activity. Lactate production measured fluorometry. Data mean Â± SEM (n = 3). *P < 0.05, unpaired 2-tailed Studentâ€™s t test.


Results                                                                        tional contribution Ndi1, respiration Ndi1-expressing MDA-
Enhancement complex activity human breast cancer cells inhibits        MB-435 MDA-MB-231 cells inhibited mammalian
tumor growth metastasis. Complex function MDA-MB-435                  complex antagonist rotenone 20  28 , respectively, MDA-MB-231 cells enhanced stable transduction                  contrast 85  84  controls. cases, oxygen 
Ndi1. encoded enzyme expressed 90  cells, local-             sumption fully blocked complex III inhibitor antimycin
ized mitochondria (Figure 1A) altering stoichiom-               (Figure 1B), indicates measurements specifically
etry mitochondrial complexes (Supplemental Figure 1; supple-                reported mitochondrial respiration. Ndi1 increased OXPHOS-
mental material available online article; doi:10.1172/               uncoupled respiration, shown oligomycin-inhibited
JCI64264DS1), significantly enhanced mitochondrial respira-                respiratory rate (Supplemental Figure 2A), enhanced com-
tion intact tumor cells (Figure 1B). Confirming func-               plex mediated respiration permeabilized cells addition

	                             Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013	                1069
 research article




Figure 2
Mitochondrial complex activity modulates tumor growth metastasis.   Ndi1 expression inhibited mammary fat pad tumor growth MDA-MB-435 MDA-MB-231 cells. Control cells transduced vector (n = 6). (B) Ndi1 expression inhibited lung colonization
(experimental metastasis) MDA-MB-435 MDA-MB-231 cells v. injection. Control cells transduced vector (n = 6). (C)
Ndi1 expression inhibited multiorgan experimental metastasis, indicated noninvasive bioluminescence imaging 7 weeks v. injection 2.5 Ã— 105 MDA-MB-435 control Ndi1-expressing cells (n = 5). (D) Knockdown complex subunit NFUFV1 expression inhibited complex activity respiratory capacity MDA-MB-435 cells. NDUFV1-knockdown (shV1) control (shCT) cells compared. Complex immunocaptured cell lysates, analyzed based oxidation NADH NAD+, expressed mean OD/min/mg protein (n = 3). Routine mito-
chondrial respiration, corrected residual oxygen consumption oxidative reactions, measured intact MDA-MB-435 control NDUFV1-knockdown cells high-resolution respirometry (n = 3). (E) NDUFV1 knockdown increased lung colonization activity MDA-MB-435
cells. NDUFV1-knockdown control cells compared (n = 8). Data mean Â± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, nonparametric
Mann-Whitney test   B, E) unpaired 2-tailed Studentâ€™s t test (D).


 complex substrates malate glutamate (Supplemental                    corroborate role aberrant complex activity metastat-
Figure 2, B C). Ndi1 did change maximal capacity                ic progression, challenged findings independent mitochondrial electron transfer (Supplemental Figure                reverse approach, asking interference tumor cell
2A). Resistance rotenone susceptibility flavone affirmed             complex function enhances metastatic aggressiveness. contribution Ndi1 (Supplemental Figure 2, B C).             end, knocked NDUFV1 MDA-MB-435 cells. NDUFV1
tumor cell models, Ndi1 did alter mtDNA content mito-                   encodes 51-kDa complex subunit, belongs chondrial membrane potential (Figure 1C). Reflecting overall ener-             minimal assembly required catalysis carries NADH
gy metabolism balance glycolysis mitochondrial                 binding site (26). Mutations gene cause complex defi-
OXPHOS, Ndi1 expression decreased ATP levels, lactate                  ciency severe neurological diseases Leigh syndrome (26).
production unchanged breast cancer cell models (Fig-               NDUFV1 knockdown (Supplemental Figure 3) reduced complex
ure 1C). results demonstrated functional integration             activity 92  cellular respiration 51  significantly
Ndi1 NADH dehydrogenase respiratory chain 2 human                  enhanced metastatic activity aggressive MDA-
cancer cell models, causing enhanced mitochondrial complex                   MB-435 cell line (Figure 2, D E).
activity major effect overall energy balance.                        results provided definitive evidence specific modula-
  investigate enhancement tumor cell complex                   tion tumor cell complex function significantly alter tumor
activity affects tumorigenicity metastasis, Ndi1-expressing                growth metastatic activity.  complex mutations
F-lucâ€“tagged MDA-MB-435 MDA-MB-231 cells followed                     primary tumors breast cancer patients (6, 11â€“14, 16) female SCID mice noninvasive bioluminescence imaging. Ndi1               play key role disease progression.
expression strikingly affected malignant phenotype tumor               Inhibition metastatic activity enhancement complex func-
cells, tumor growth rates mammary fat pad metastasis             tion depends autophagy. investigate complex activity bloodstream significantly reduced (Figure 2, C).               affects tumor growth metastasis, analyzed effects

1070	                         Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013
                                                                                                                                  research article




Figure 3
Mitochondrial complex activity regulates mTORC1 autophagy.   Ndi1 expression enhanced resistance glucose deprivation MDA-
MB-231 cells, shown 72 hours incubation medium 5 versus 1 mM glucose. Viability measured flow cytometry (nonâ€“sub-
G0/G1 population). n = 3 independent analyses. *P < 0.05, unpaired 2-tailed Studentâ€™s t test. (B) Ndi1 expression influenced mTORC1 activity autophagy. Western blot analysis p62, phospho-AKT substrates, mTORC1 kinaseâ€“related substrates phospho-S6Ser240/244 phospho-4EBPThr37/46 MDA-MB-435 MDA-MB-231 control Ndi1-expressing cells. Î²-Tubulin used protein loading control. Signal
quantification, measured infrared imaging (total detectable bands) expressed relative control, shown  Results represen-
tative 5 independent experiments. Lanes run gel noncontiguous (white lines). (C) H&E staining p62, Ki67, Ndi1 expression mammary fat pad tumors 5 weeks implanting 2.5 Ã— 105 MDA-MB-435 control versus Ndi1-expressing cells SCID mice.
2 representative tumors 6 shown group. Original magnification, Ã—10. (D) Inhibition complex activity NDUFV1 knockdown
affected mTORC1 activity p62 elimination. Western blot analysis p62, phospho-AKT substrates, phospho-S6 Ser240/244, phospho-
4EBPThr37/46, comparing NDUFV1-knockdown versus control MDA-MB-435 cells. Signal quantification, measured infrared imaging (total detectable bands) expressed relative control, shown  Results representative 3 independent experiments. Lanes run gel noncontiguous (white lines).




	                             Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013	                1071
 research article




Figure 4
Metastasis inhibition enhanced complex activity depends autophagy.   ATG5 knockdown (shATG5) inhibited autophagy MDA-MB-435 MDA-MB-231 control Ndi1-expressing cells, shown p62 LC3BI accumulation. Signal quantification ATG5, p62 signal, LC3BI/II ratios, measured infrared imaging (total detectable bands) expressed relative control, shown  Î²-Tubulin served protein loading control. Lanes run gel noncontiguous (white lines). (B) ATG5 knockdown blocked antimetastatic
effect Ndi1 MDA-MB-435 MDA-MB-231 cells. Lung colonization measured ex vivo lung imaging 7 weeks v. injection 2.5 Ã— 105 tumor cells (n = 8 group). Boxes denote interquartile range; lines boxes denote median; whiskers denote minima maxima.
*P < 0.05, nonparametric Mann-Whitney test. (C) ATG5 knockdown enhanced multiorgan metastasis reversed metastasis inhibition Ndi1 MDA-MB-435 cells. Shown noninvasive bioluminescence imaging 5 representative mice group 7 weeks tail vein injection 2.5 Ã— 105 MDA-MB-435 control Ndi1-expressing cells, ATG5 knockdown.


 Ndi1 expression tumor cell viability growth.                   based levels phospho-AKT substrates. Ndi1 clearly reduced
Ndi1 did affect proliferation vitro (Supplemental Figure                AKT activity MDA-MB-231 cells inhibited mTORC1 4, B), Ndi1 increased resistance glucose deprivation               cell lines (Figure 3B), suggested complex activ-
MDA-MB-231 cells (Figure 3A) suppressed tumorigenicity                     ity induce autophagy regulating mTORC1 signaling. cell lines (Figure 2A). similar paradoxical phenomenon               process likely involves AKT MDA-MB-231 cells alternative previously described linked ability tumor cells              mechanisms MDA-MB-435 cells. undergo autophagy (27â€“29), indication time                     Importantly, levels p62 Ki67 strongly decreased mitochondrial complex involved. Following                  primary tumors expressing Ndi1 (Figure 3C), indicates hypothesis breast cancer cell complex activity affect               enhancement complex increases tumor cell autophagy autophagy, analyzed effects Ndi1 expression p62,                inhibits proliferation vivo. conclusion strongly sup-
ubiquitin-binding scaffolding protein eliminated                ported enhancement AKT mTORC1 activities clear
autophagy (27, 30). Ndi1 expression increased p62 degradation                  inhibition p62 elimination NDUFV1 knockdown, (Figure 3B), indicated enhancement mitochon-                     reduced complex functionality tumor cells (Figure 3D) 
drial complex activity induced autophagy. Following signaling                affecting proliferation (Supplemental Figure 4C). pathways regulate autophagy, analyzed effects Ndi1                  results demonstrated tumor cell complex activity regulate mTORC1 activity AKT, mTORâ€™s main regula-                         tumor cell mTORC1 signaling autophagy vitro vivo.
tors. mTORC1 activity measured phosphorylation                         analyze directly complex mediated regulation mTORC1-related substrates S6 4EBP1; AKT activity                       breast cancer metastasis involves control tumor cell autoph-

1072	                         Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013
                                                                                                                                 research article




Figure 5
NAD+ level modulation complex NAD+ synthesis recycling pathways regulate AKT/mTORC1 activity, autophagy, metastasis.  
Ndi1 expression enhanced NAD+/NADH balance. NAD+/NADH ratios cell mitochondrial extracts MDA-MB-435 MDA-MB-231
control versus Ndi1-expressing cells. Ndi1 stabilized NAD+/NADH ratios, especially metabolic stress induced glucose deprivation hypoxia. NAD+/NADH ratios stress measured cell extracts 48 hours culture. (B) Interference NAD+ synthesis recycling pathways reduced NAD+/NADH ratios. Knockdown NAMPT (shNAMPT) MDA-MB-435 MDA-MB-231 cells decreased
NAD+/NADH ratios  cell extracts 48 hours growth 5 mM glucose normoxia). (C) NAMPT knockdown increased lung coloniza-
tion activity MDA-MB-435 MDA-MB-231 cells (n = 6 group). (D) NAMPT knockdown affected mTORC1 activity p62 elimination.
Western blot analysis p62, phospho-AKT substrates, phospho-S6Ser240/244, phospho-4EBPThr37/46 MDA-MB-435 MDA-MB-231
NAMPT-knockdown versus control cells. Î²-Tubulin served protein loading control. Signal quantification, measured infrared imaging (total detectable bands) expressed relative control, shown  Lanes run gel noncontiguous (white lines).
Results representative 3 independent experiments.  C) Data mean Â± SEM. *P < 0.05, **P < 0.01, unpaired 2-tailed Studentâ€™s t test
 B) nonparametric Mann-Whitney test (C).



agy, knocked ATG5, protein required autophagy                     NAD+ level modulation complex alteration NAD+ synthesis
induction (31). Targeting ATG5 control Ndi1-expressing                 recycling pathways regulate AKT/mTORC1 activity, autophagy, MDA-MB-435 MDA-MB-231 cells stable transduction                        metastatic activity. investigate mechanism shRNA (Figure 4A Supplemental Figure 5A) inhibit-                    enhancement complex activity inhibits tumor progression,
ed autophagy, shown p62 LC3BI accumulation (Fig-                    ruled alterations ROS NADPH production
ure 4A), affecting proliferation vitro (Supplemental               major underlying causes. Ndi1 expression MDA-MB-435
Figure 5B). Importantly, basal levels autophagy                   MDA-MB-231 cells did significantly alter ROS levels facilitated metastasis MDA-MB-231 cells, ATG5 knockdown                    NADPH-reducing equivalents (Supplemental Figure 6, B).
abolished inhibitory effect Ndi1-mediated complex                    Likewise, NDUFV1 knockdown did significantly affect ROS
enhancement metastatic organ colonization (Figure 4, B                 (Supplemental Figure 6C), suggests enhancement C). seen primarily lungs MDA-MB-231                complex activity Ndi1 inhibits tumorigenicity metastasis
multiple organs MDA-MB-435, including lung, liver, bone,                  ROS-independent manner.
brain, adrenal glands. findings affirm conclusion                 major function mammalian complex Ndi1 NADH inhibition metastasis enhancement mito-                    dehydrogenase activity. Ndi1 expression MDA-MB-435 chondrial complex activity depends autophagy induction                MDA-MB-231 cells increased NAD+/NADH ratios cell
2 aggressive tumor cell models.                                               extracts purified mitochondria, particularly metabolic

	                            Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013	                 1073
 research article




Figure 6
NAD+ precursor treatment inhibits metastatic activity.   NAD+ precursor treatment enhanced NAD+/NADH ratio cultured MDA-MB-435 MDA-MB-231 parental cells. NAD+/NADH levels measured 3 days cell treatment 10 mM NIC NAM complete medium. n = 3
independent experiments. (B C) NAD+ precursor treatment experimental mice inhibited lung metastasis. Lung colonization MDA-MB-435
(B) MDA-MB-231 (C) parental cells (2.5 Ã— 105 v.  mice treated NIC NAM (1  drinking water ad libitum experiment). Controls received treatment (plain drinking water pH). Metastatic growth measured repeated noninvasive biolu-
minescence imaging. n = 6 group. (D) NIC NAM treatment influenced mTORC1 activity autophagy. Western blot analysis p62, phos-
pho-AKT substrates, phospho-S6Ser240/244 MDA-MB-435 MDA-MB-231 parental cells 48 hours treatment 10 mM
NIC NAM. Î²-Tubulin served protein loading control. Signal quantification, measured infrared imaging (total detectable bands) expressed relative control, shown  Results representative 3 independent experiments. *P < 0.05, **P < 0.01, unpaired 2-tailed
Studentâ€™s t test   nonparametric Mann-Whitney test (B C).



stress induced glucose oxygen deprivation (Figure 5A).                MB-231 cells (Figure 5C), indicative cause effect relation-
culture, Ndi1-mediated increase NAD+/NADH ratios                     ship reduced NAD+/NADH ratios metastatic activity.
measurable exponential cell growth (Supplemental Fig-                   increased metastatic activity interference cellu-
ure 7, B). Conversely, disturbance endogenous complex                 lar NAD+/NADH ratios involved altered mTORC1 activity activity NDUFV1 knockdown reduced NAD+/NADH ratios                       autophagy. NAMPT-knockdown cells analyzed normal
(Supplemental Figure 8). reasoned modulation cel-               conditions glucose deprivation. metabolic stress lular redox potential (NAD+/NADH ratio) mitochondrial com-                  glucose deprivation (1 mM glucose), NAMPT knockdown induced
plex activity regulate metastatic activity tumor cells.           p62 accumulation enhanced AKT mTORC1 activities test hypothesis using independent approach, experi-              (Figure 5D), indicated NAD+ levels regulate AKT/
mentally decreased NAD+/NADH ratios MDA-MB-435                          mTORC1 signaling autophagy pathways MDA-MB-435
MDA-MB-231 cells analyzed effect metastasis vivo.                MDA-MB-231 cells.
  decrease NAD+/NADH ratio tumor cells, dis-                    results showed downregulation NAMPT
turbed NAD+ synthesis recycling pathway targeting                   expression enhanced metastatic activity, chemical NAMPT inhibi-
nicotinamide phosphoribosyltransferase (NAMPT). NAMPT                       tors previously suggested anticancer therapy (33).
essential utilization recycling nicotinamide (NAM)              investigate potential discrepancy, analyzed effects biosynthesis NAD+ (32). Interference NAMPT expres-                 FK866, noncompetitive inhibitor NAMPT (34), vitro sion stable transduction shRNA (Supplemental                      vivo. vitro, FK866 decreased cellular NAD+/NADH ratios Figure 9A) reduced cellular NAD+/NADH ratios (Figure 5B), inde-                MDA-MB-435 MDA-MB-231 cells levels similar pendently growth state tumor cells (Supplemental                 seen NAMPT knockdown (Supplemental Figure 11A), indica-
Figure 10, B) affecting cell proliferation vitro          tive effect drug NAD metabolism. Treatment (Supplemental Figure 9B). vivo,  NAMPT knockdown                    NAMPT-knockdown cells FK866 reduced NAD+/NADH lev-
significantly enhanced metastasis MDA-MB-435 MDA-                       els  likely dose effect NAMPT inhibition (Sup-

1074	                         Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013
                                                                                                                                  research article




Figure 7
NAD+ precursor treatment primary breast tumor removal increases animal survival.   NAM treatment enhanced NAD+/NADH ratio cultured 4T1 murine breast carcinoma cells. NAD+/NADH levels measured 2 days cell treatment 10 mM NAM complete
medium. **P < 0.01, unpaired 2-tailed Studentâ€™s t test. n = 2 independent experiments. (B) Weight 4T1 mammary fat pad tumors untreated
BALB/c mice. Tumors surgically removed volume reached 300 mm3. Data tumor weight distribution time surgery randomization groups (n = 8), treatment initiated. Boxes denote interquartile range; lines boxes denote median; whiskers
denote minima maxima. P = 0.7480, unpaired 2-tailed Studentâ€™s t test. (C) Kaplan-Meier curves comparing survival NAM-treated untreated BALB/c mice surgical removal 4T1 mammary fat pad tumors. Mice untreated treated 1  NAM drinking water tumor removal (assigned day 0). n = 8 group. P = 0.0386, log-rank test.


plemental Figure 11A). vivo, FK866 did reduce metastatic activ-             independent cell model preferably seeds brain metas-
ity 42-day observation period (Supplemental Figure 11B).                tases bloodstream. MDA-MB-453 cells, HER2+ cell vivo effect related cytotoxic properties            line derived pericardial effusion breast cancer patient
drug. genetic interference tumor cell NAMPT expres-                 brain lesions (35), injected left cardiac ventricle.
sion did affect cell growth cause cell death vitro (Supple-          Brain metastasis significantly reduced animals receiving
mental Figure 9B), FK866 treatment induced S-G2/M cell cycle                   NAM treatment (Supplemental Figure 14, B).
arrest necrosis (Supplemental Figure 11, C D). cyto-                  sought analyze mechanisms involved anti-
toxic effects FK866 enhanced NAMPT-knockdown cells.                 metastatic activity NAD+ precursor treatment. results indicate drug, originally identified cell         NIC NAM increased p62 degradation, indicative autophagy
proliferation inhibitor high-throughput screen, exerts effects            induction, decreasing AKT mTORC1 activities MDA- cell viability. Concentrations FK866 reduced NAD+/                  MB-435 MDA-MB-231 cells (Figure 6D).  NAD+
NADH ratios tumor cells NAMPT knockdown                      modulation NIC NAM treatment significantly reduced
did caused significant cell death vitro, genetic NAMPT              mtDNA content, indicative mitophagy, 3-day exposure
interference did   cytotoxic effects drug              changing mitochondrial distribution tumor related NAMPT inhibition                                       cells (Supplemental Figure 15). results consistent   NAD+ precursor treatment inhibits metastasis spontaneous breast          observed regulation AKT/mTORC1 signaling autopha-
cancer progression. Having demonstrated reduced nonlethal             gy enhancement NAD+/NADH ratios MDA-MB-435
NAD+/NADH ratios enhanced metastatic activity, reasoned                     MDA-MB-231 cells expression Ndi1 enhance mito- increasing NAD+/NADH balance interfere                     chondrial complex activity (Figure 3).
metastatic progression. test hypothesis, MDA-MB-435                      reported SIRT1, NAD+-dependent deacetylase MDA-MB-231 cells treated NAD+ precursors                     (36), sense increased NAD+/NADH levels induced NAM nicotinic acid (NIC) NAM. NAM induce stronger increases                 inhibit mTORC1 activate autophagy (37). inves- NAD+ levels NIC, high concentrations, NAM                   tigated possible involvement SIRT1 NAM treatmentâ€“ increases NAD+ synthesis, inhibit NAD+                   induced autophagy models. targeted SIRT1 expres-
consumption NAD+-dependent enzymes (33). MDA-MB-231                      sion MDA-MB-435, MDA-MB-231, MDA-MB-453 cells MDA-MB-435 cells, NAD+/NADH ratios significantly                      stable transduction shRNA (Supplemental Figure 16A).
enhanced NIC NAM (Figure 6A), independent prolif-                 Her2+ MDA-MB-453 cell line, SIRT1 knockdown blocked
eration state tumor cells time treatment (Supple-             NAM-mediated inhibition mTORC1 activity induction mental Figure 12, B). importantly, affect-                autophagy.  seen triple-negative MDA-
ing cell growth vitro (Supplemental Figure 13A), treatment               MB-435 MDA-MB-231 cell lines (Supplemental Figure 16B).
experimental animals NAD+ precursors given drinking                 NAM treatment modulated mTORC1 autophagy
water strongly reduced lung metastasis cell lines v.           tested cell lines, SIRT1 involvement clearly evident injection (Figure 6, B C).  treatment clearly           cases,  additional alternative
interfered multiorgan metastasis MDA-MB-435 cells,                  mechanisms required. brain lesions notably reduced (Supplemental                      results Ndi1 expression NAMPT
Figure 13B). striking antimetastatic effect confirmed                 knockdown, findings demonstrated specific modulation

	                             Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013	                   1075
 research article




1076	              Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013
                                                                                                                                  research article

Figure 8                                                                       MT634 strain (38). MMTV-PyMT model emulates important
NAD+ precursor treatment inhibits spontaneous breast cancer pro-               aspects human breast cancer progression replicates distinct
gression MMTV-PYMT mice.   NAM treatment (1  drinking                  advancing stages breast cancer pathology, making highly useful
water experiment, beginning weaning) reduced mam-
                                                                               preclinical therapeutic trials (39). MT634 strain MMTV-PyMT
mary tumor growth. Weights 10 mammary fat pads treated mouse (n = 10), untreated control mice (n = 11), untreated
                                                                               mice received 1  NAM drinking water beginning wean-
age- strain-matched PyMT-negative mice (Normal; n = 3). Boxes              ing (day 22) continuing experiment. Controls
denote interquartile range; lines boxes denote median; whiskers         received water NAM. Tumor mass, histological grade, denote minima maxima. ***P < 0.001, nonparametric Mann-Whit-               lung metastasis examined day 80. Importantly, NAD+ pre-
ney test. (B) Fat pads untreated versus NAM-treated PyMT mice,              cursor treatment strongly interfered oncogene-driven breast
representative 10 fat pad locations. (C) NAM treatment inhibited        cancer progression MMTV-PyMT mouse model (Figure 8).
PyMT-induced breast cancer progression. Percent area morphologi-            Mammary fat pad tumor mass significantly reduced NAM-
cal stages 8 representative fat pads untreated (PyMT-Ctrl)                                                                                treated mice. cases, mammary fat pads treated mice NAM-treated (PyMT-NAM) mice. Averages group shown  Scoring hyperplasia, adenoma, early advanced car-            normal minimal tumor involvement (Figure 8, B, cinoma performed slide scans H&E-stained tumor                 Supplemental Figure 17). Weight analysis individual fat pad
sections morphometric measurements. (D) Representative micro-               mouse showed 6.8 Â± 0.6 10 fat pads mouse scopic fields 2 H&E-stained sections 4 tumors untreated             control group (n = 11) larger largest fat pad NAM-treated PyMT mice. Scale bars: 200 Î¼m  row                PyMT-negative mice strain age. true treatment group); 50 Î¼m  row). (E) Quantification Western            0.6 Â± 0.4 10 fat pads mouse NAM treatment group
blot analyses mammary tumors control NAM-treated PyMT              (n = 10; Supplemental Figure 17). reported weights include mice (n = 8 tumors group). Shown relative protein abundance
                                                                               fat pads mouse, regardless tumor presence. Importantly, p62, phospho-S6Ser240/244, phospho-4EBPThr37/46. Boxes denote
interquartile range; lines boxes denote median; whiskers denote         histopathological analysis revealed NAM treatment drastically
minima maxima. ***P < 0.001, unpaired 2-tailed Studentâ€™s t test.           inhibited breast cancer progression (Figure 8, C D, Supple-
                                                                               mental Figure 18). untreated MMTV-PyMT mice tumors
                                                                               primarily containing adenoma, early advanced carcinoma, NAD+/NADH ratios, altering mitochondrial complex                  little normal hyperplastic tissue. contrast, NAM-treated mice activity, affecting NAD+ synthesis recovery pathways,           normal mammary fat pads; tumors,  small treating cells experimental animals NAD+ precursors,              consisted predominantly hyperplastic adenoma tissue. Fur-
markedly change metastatic activity outcomes vivo.                      thermore, lung metastases detected 4 7 untreated
   challenge concept NAD+ precursor treatment                  animals, metastases NAM-treated MMTV-PyMT
interfere tumor growth metastatic activity, asked                  mice (0 6), assessed comprehensive histology serial lung therapeutic approach inhibit spontaneous                    sections (data shown). Importantly, NAM treatment induced
metastasis prolong animal survival surgical removal             autophagy PyMT mammary tumors vivo, shown p62
primary breast tumor. test hypothesis, used aggres-             degradation Western blot analyses individual tumors (Fig-
sive metastatic, triple-negative breast cancer cell model 4T1.              ure 8E Supplemental Figure 19). did detect effects vitro, addition NAM significantly enhanced NAD+/NADH ratios                 mTORC1 activity regulation, suggests NAM treatment 4T1 cells (Figure 7A), indicative response NAD+ precursor           drinking water transiently modulate mTORC1 activity
treatment. analyze therapeutic effects NAM treatment              PyMT mammary tumors vivo.
animal model, F-lucâ€“tagged 4T1 cells injected fourth                  challenge concept NAD+ precursor treatment mammary fat pad immunocompetent BALB/c mice, tumors                     interfere breast cancer progression, analyzed effects removed surgically reached volume 300 mm3.                 NAM treatment MMTV-PyMT mice estab- time surgical removal, mice randomized                 lished spontaneous mammary tumors. Mice received 1  NAM
trol (untreated water) NAD+ precursor treatment (1  NAM                 drinking water, starting day 60 multiple pal-
drinking water remainder experiment) groups (n = 8              pable tumors present animal. Controls received , tumor weights measured (Figure 7B). time                water NAM. Tumor masses examined day 80. surgery NAM treatment, 1 animal group                Importantly, NAD+ precursor treatment significantly inhib-
spontaneous metastasis lungs, measured noninvasive                ited growth established mammary tumors, bioluminescence imaging. 1 week tumor removal, 7 8                 delayed onset therapy (Supplemental Figure 20).
control mice 5 8 NAM-treated mice detectable metas-                     findings demonstrated NAD+ precursor
tases. 2 weeks, 8 8 controls 6 8 NAM-treated mice              treatment induce autophagy vivo effectively interfere
showed metastasis. end experiment (day 70 sur-             breast cancer progression stages oncogene-driven
gery), 1 animal treatment group detectable recur-          breast cancer development.
rence. Importantly, NAM treatment starting primary tumor
surgery significantly increased animal survival model               Discussion
highly aggressive metastatic breast cancer (Figure 7C).                        present findings establish tumor cell NAD+/NADH
   asked therapeutic approach gener-                balance controlled mitochondrial complex regulate breast
ally interfere breast cancer progression. test hypothesis,        cancer progression. enhancement complex used MMTV-PyMT mouse model, polyoma middle                     activity expression NADH dehydrogenase Ndi1 T (PyMT) oncogene expression mammary epithelium leads                   Saccharomyces cerevisiae strongly interfered tumor growth multifocal mammary tumor formation, detectable 30 days                metastasis, inhibition complex knockdown age, progression lung metastasis, detectable 80 days,         subunit NDUFV1 enhanced metastatic potential 
	                             Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013	                 1077
 research article

aggressive breast cancer cells. Mutations complex report-           metastatic animal models. possible FK866 induc-
ed human breast tumors (6, 9â€“12). mtDNA mutations se                   es cellular stress alternative mechanisms addition known cause transformation (40), contribute                depleting NAD+ levels NAMPT inhibition. cancer progression, seen lung carcinoma EGFR muta-                Controversial effects reported ROS-inducing
tions (41) oncocytic tumors loss complex function            therapies. cancer treatments induce high ROS levels
(14, 42). Furthermore, oncogene activity (e.g., K-Ras transforma-             kill tumor cells, nonlethal increase ROS facilitate tumor
tion) decrease mitochondrial complex activity (43),               progression metastasis (7, 49). similar concept applies support malignant phenotype (44). results revealed                  present findings, NDUFV1 knockdown caused com- cause effect relationship complex function                plex deficiency did drastically inhibit OXPHOS. breast cancer progression.                                                    affecting cell viability, NDUFV1 knockdown significantly
  Enhancement complex activity Ndi1 did alter                enhanced metastatic activity.  noted strate-
tumor cell proliferation vitro, clearly reduced tumor growth           gies aimed killing tumor cells interfering mitochondrial metastasis vivo. Changing access nutrients oxygen               functions NAD+ synthesis  effectively lethal, inad- tumor microenvironment influences cell survival                vertently produce aggressive tumor cell phenotypes.
proliferation. conditions, growth regulation               long run, approaches aimed normalizing mito-
complex critical. mechanism                   chondrial functions, particularly complex activity NAD+/
depended autophagy. Enhancement complex Ndi1                  NADH redox levels, therapeutically effective reduced metastasis induced p62 elimination, com-                  safer interfere normal cell function.
plex inhibition NDUFV1 knockdown enhanced metastasis                       Having established enhancement NAD+/NADH levels reduced p62 processing. critical contribution autoph-              augmenting breast cancer cell complex activity inhibited tumori-
agy clear ATG5 knockdown, abrogated                     genicity metastasis, used new concept therapeutically
antimetastatic effect Ndi1 breast cancer cell models.              hypothesized supplementing tumor cell nutrients Consistent previous reports (45), basal levels             NAD+ precursors, NIC NAM, interfere breast autophagy facilitated metastasis MDA-MB-231 cells;             cancer progression. NIC NAM used modulate NAD+ seen MDA-MB-435 cells. Autophagy inhibit promote                levels showed therapeutic effects disorders, cerebral
tumorigenesis supporting tumor cell survival metabolic               ischemia, diabetes, cardiovascular dysfunctions (32, 33). NIC
stress (27â€“29). results support dual role autophagy,           NAM protect neurons oxidative damage, sub-
clearly showing autophagy required mitochondrial                 clinical vitamin B3 deficiency associated genomic instabil-
complex mediated reduction metastatic growth.                 ity increased cancer risk (50).
main regulators autophagy mTORC1, links tumor                       demonstrated enhancing NAD+ levels NAD+
growth metabolism (46). mitochondrial com-                  precursor treatment effectively inhibited experimental metas-
plex modulated mTORC1 upstream regulator, AKT,                      tasis human breast cancer cells xenograft models. Impor- breast cancer cells, suggesting mTORC1 likely pathway                 tantly, treatment inhibited spontaneous metastasis complex regulates autophagy.                                  increased animal survival therapy begun sur-
  results demonstrated mitochondrial complex                   gical removal primary tumors. Furthermore, NAD+ precursor
control breast cancer progression regulating cellular                  treatment strongly interfered oncogene-driven breast cancer
NAD+/NADH balance. Ndi1 expression enhanced redox                        development progression transgenic MMTV-PyMT mice.
balance, particularly metabolic stress, indicates               results provide evidence mechanism involves induc-
involvement strong inhibition tumorigenicity metas-                 tion autophagy. NAD+ precursor treatment activated tumor cell
tasis Ndi1. consolidate role complex                    autophagy vitro vivo included regulation trolled NAD+/NADH ratio modulation breast cancer progres-                  mTORC1 activity, seen culture. reported mod-
sion, experimentally altered tumor cell NAD+/NADH ratios                   ulation NAD+/NADH ratios affect PI3K/AKT survival
using 2 additional independent approaches.  interfered               pathway inactivation PTEN (51). Furthermore, NAD+- NAD+ biosynthesis recycling pathways knockdown                    dependent sirtuins modulate mTORC1 regulation of NAMPT reduce NAD+/NADH balance. Second,                          TSC2 (52) LKB1 activity (53, 54). Sirtuins affect autoph-
enhanced NAD+/NADH balance treatment NAD+ pre-                    agy controlling FOXO3 degradation (55) directly regulating
cursors. Importantly, decreasing NAD+/NADH ratios knock-                   autophagy proteins ATG5, ATG7, ATG8 (56). NAMPT, rate-limiting enzyme NAD+ synthesis                   modulation mTORC1 activity autophagy NAM involved
pathway converts NAM NAD+, significantly enhanced                     SIRT1 activation MDA-MB-453 cells, likely depends metastatic activity aggressive human breast cancer                 additional alternative mechanisms MDA-MB-435 MDA-
cells. NAMPT knockdown enhanced AKT/mTORC1 activities                         MB-231 cells. NAD+-dependent sirtuins PARPs contribute inhibited autophagy. apparent opposition, recent study               p53 function regulate chromatin structure genomic stabil-
reported NAMPT inhibition reduced prostate cancer cell                   ity (32, 33, 50), playing emerging roles tumor progression
viability (47). NAMPT suggested therapeutic                (57).  transcriptional corepressor CtBP responds target inhibition progression breast cancer (48)             increased NADH hypoxia permit gene expression pro-
malignancies (33). chemical NAMPT inhibitor                 motes tumor cell migration (58). Importantly, BRCA1 tumor sup-
FK866 induced cell death vitro tumoricidal effects              pressor expression inhibited low NAD+/NADH ratios (59, 60).
vivo. contrast, genetic interference NAMPT expression                present study demonstrated mitochondrial complex breast cancer cells did inhibit tumor cell viability           regulation tumor cell NAD+/NADH levels affects breast  killing tumor cells, rendered aggressive               cer growth metastasis translated new therapeutic

1078	                        Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013
                                                                                                                                       research article

approach preventing breast cancer progression. highly                 defined regions using Living Image software. MMTV-PyMT
relevant, current standard care cancer patients relies              mice (strain MT634; gift W.J. Muller, McGill University, Montreal, Quebec,
primarily chemo- radiation therapies aimed killing                  Canada; ref. 38) heterozygous PyMT transgene genotyped
tumor cells. Evolutionary models predict selective pressure                  PCR using forward primer 5â€²-CGGCGGAGCGAGGAACTGAGGAGAG-3â€²
imposed approaches causes survival resistant clones                   reverse primer 5â€²-TCAGAAGACTCGGCAGTCTTAGGCG-3â€². NAD+ eventually reactivate disease (61). Based central                 precursor treatment, mice received 1  NIC NAM drinking water,
involvement metabolic tumor cell alterations cancer, thera-                 changed weekly. histology, mammary fat pads lungs peutic normalization tumor cell metabolism interfere                     zinc fixed, sectioned serially (5 Î¼m), H&E stained. PyMT model, expansion residual breakthrough clones.                    scoring 4 morphological stages (hyperplasia, adenoma, early carcinoma,
combination standard therapy NAD+ precursor treatment                     advanced carcinoma; ref. 39) performed slide scans (Leica halt breast cancer progression prevent relapse.                           SCN400 Digital Slide Scanner) image analysis morphometric mea-
                                                                                  surements (Metamorph imaging software; version 7.6). Select regions Methods                                                                           imaged using Zeiss Axio Imager M1m microscope AxioVision software.
Cell culture. MDA-MB-231, MDA-MB-435, MDA-MB-453, 4T1 cells                Lung metastases MMTV-PyMT mice quantified 10 H&E-stained variants stably transduced Firefly luciferase (F-luc)     step sections lung (5 Î¼m  80 Î¼m apart).
using lentiviral expression vector cFUW (ubiquitin promoter; provided                Ndi1 integration cellular respiration. 2 Ã— 106 cells collected B.E. Torbett, Scripps Research Institute) analyze tumor growth          complete medium, respiration measured 37Â°C 2-ml cham- metastasis noninvasive bioluminescence imaging (62). Cells            ber high-resolution respirometry using Oroboros Oxygraph series
grown EMEM supplemented nonessential amino acids, vitamins,               D DatLab software (Oroboros Instruments). Routine mitochondrial
2 mM l-glutamine, 1 mM pyruvate, 10  FBS (complete medium).               respiration, corrected residual oxygen consumption oxidative
metabolic stress, cells cultured Neurobasal Medium (Gibco) sup-         reactions, measured intact cells complete medium. Func-
plemented nonessential amino acids, vitamins, 2 mM l-glutamine,              tional integration Ndi1 tumor cell mitochondrial respiration 5 mM 1 mM glucose, 2  dialyzed FBS normoxia (21  oxygen)             determined oxygen consumption addition rotenone (2.5 Î¼M) hypoxia (<1  oxygen; Modular Incubator Chamber; Billups-Rothenberg).              inhibit endogenous complex final addition complex III inhibitor
   Ndi1 expression. Tumor cells stably transduced Ndi1 gene         antimycin (2.5 Î¼M) terminate mitochondrial respiration. S. cerevisiae (19) subcloned lentiviral expression vector cFUW.            Enzymatic analysis mitochondrial complex activity. NADH oxidation Transduced cells used pools experiments. Ndi1 expression           NAD+ complex analyzed using immunocapture complex analyzed Western analysis, subcellular localization ana-           enzyme activity assay (MS-141; MitoSciences).
lyzed immunofluorescence, described previously (18).                           NAD+/NADH analysis cell mitochondrial extracts. NAD+    NDUFV1, NAMPT, ATG5 knockdown. Lentiviral vectors contain-                 NADH analyzed independently extracts cells (1 Ã— 106) ing shRNA NDUFV1 (clone TRCN0000025872), ATG5 (clone                      isolated mitochondria  1 Ã— 107 cells) prepared described previously
TRCN0000151963), NAMPT (clone TRCN0000116180), nontargeting                    (18, 63). Concentrations determined using NAD/NADH fluores-
control shRNA (SHC0002) Sigma-Aldrich. Knockdown effi-                  cence detection kit (Cell Technology ).
ciency quantified real-time PCR using FastStart Universal SYBR                mtDNA. mtDNA content determined quantitative real-time PCR
Green Master (Rox) (Roche) following primers: ATG5 forward,               total DNA extracted 2 Ã— 106 cells. PCR reactions performed TGGGATTGCAAAATGACAGA; ATG5 reverse, TTCCCCATCTTCAG-                               quadruplicates using TaqMan probes specific MT-RNR1 (mitochondri-
GATC AA; NAMPT ward, GCC AGC AGGGAATTTTGTTA;                                  al S12 RNA) (Hs02596859_g1, FAM label) referenced RPPH1 (RNase P,
NAMPT reverse, TGATGTGCTGCTTCCAGTTC; NDUFV1 forward,                              VIC label), nuclear gene. PCR data recorded analyzed using AAGGTTCCCTGAGTCGAGGT; NDUFV1 reverse, TTGTGAGGATCATG-                             ABI-PRISM 7700 Sequence Detection (Applied Biosystems) GCGTAA; GAPDH forward, GGGAAGGTGAAGGTCGGAGT; GAPDH                                Sequence Detector Software (version 2.0; SDS).
reverse, TCCACTTTACCAGAGTTAAAAGCAG. Data recorded                           ATP measurements. ATP extracted cell pellets (2 Ã— 106 cells) analyzed using ABI-PRISM 7700 Sequence Detection (Applied               triplicates 100 Î¼l ice-cold 2M perchloric acid. Extracts left Biosystems) Sequence Detector Software (version 2.0; SDS).                    ice 15 minutes, mixed, centrifuged 12,000 g 5 minutes    Animal experiments. experimental metastasis, female 6- 8-week-old       4Â°C. supernatant neutralized 35 Î¼l 1M Bicine 4M potas-
C.B-17/SCID mice injected F-lucâ€“tagged cancer cells: 2.5 Ã— 105 MDA-     sium carbonate pH 7.5 kept ice 15 minutes. centrifuga-
MB-231 MDA-MB-435 cells v., 5 Ã— 105 MDA-MB-453 cells left        tion, ATP concentrations measured supernatant based ATP-
cardiac ventricle stereotactic guidance. primary tumor growth,          dependent luciferase activity using ATP determination kit (Invitrogen).
1 Ã— 106 MDA-MB-231 cells 2.5 Ã— 105 MDA-MB-435 cells injected            Lactate production. Lactate concentrations measured triplicates axillary mammary fat pad. spontaneous metastasis, female 8-week-          conditioned media culturing 105 cells 6 plates (1.5 ml
old BALB/c mice injected 1 Ã— 105 F-lucâ€“tagged 4T1 cells        medium  48 hours. 500 Î¼l medium deproteinized 166 Î¼l
fourth mammary fat pad. Tumors removed surgically reached          ice-cold 2M perchloric acid, left ice 15 minutes, mixed, centri-
300 mm3 size, animals euthanized moribund determine           fuged 12,000 g 10 minutes 4Â°C. Supernatants neutralized
survival. Mice imaged weekly (IVIS 200; Xenogen) 10 minutes p.       58 Î¼l 1M Bicine 4M potassium carbonate pH 7 kept
injection d-luciferin (100 mg/kg). assess brain metastasis MDA-        ice 20 minutes. centrifugation, lactate concentrations MB-453 cells, mice imaged directly cardiac injection validate       supernatants determined fluorimetrically 340 nm excitation correct routing verifying tumor cell signal brain region lack    466 nm emission (460 nm) 60 minutes addition lactate
signal lungs. ex vivo organ imaging end experimental     dehydrogenase, described previously (5).
spontaneous metastasis studies, mice injected luciferin 5 minutes          Analysis mitochondrial membrane potential cell viability. membrane necropsy. survival analyses, imaging validated metastasis      potentialâ€“sensitive fluorochrome tetramethylrhodamine methyl ester cause moribundity. Bioluminescence quantified photons/s/cm2         (TMRM; Invitrogen) used measure mitochondrial membrane poten-

	                                Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013	                            1079
 research article

tial. Cells incubated 150 nM TMRM 30 minutes 37Â°C                       Statistics. Statistical comparisons 2 groups performed using dark analyzed flow cytometry (FACSCalibur). Data                     unpaired 2-tailed Studentâ€™s t tests unequal variance vitro results;
10,000 events sample collected analyzed measuring FL-2                    nonparametric Mann-Whitney tests vivo results, normal distri-
fluorescence using CellQuest software. Cell viability analyzed mea-                bution assumed; Kaplan-Meier curves log-rank test
suring percentage nonhypodiploid population (nonâ€“sub-G0/G1)                    animal survival. Statistical calculations performed GraphPad flow cytometry. Cells fixed ice-cold 70  ethanol, washed                  Prism software. P value 0.05 considered significant. Results
PBS, incubated 50 Î¼g/ml propidium iodide 100 Î¼g/ml                           shown mean Â± SEM values obtained independent experiments.
RNAse 30 minutes 37Â°C. Data 20,000 events sample                     Study approval. Animal studies approved Institutional Animal
collected measuring FL-2 fluorescence.                                                 Care Use Committee Scripps Research Institute. Animal work
   Immunohistochemistry. Tumor tissues paraformaldehyde zinc                      complied NIH institutional guidelines  Scripps Research
fixed, paraffin embedded, sectioned (5 Î¼m), transferred glass slides,                Institute AAALAC accredited).
deparaffinized safe clear II, rehydrated series ethanol solu-
tions. p62, Ki67, Ndi1 staining performed antigen retrieval                  Acknowledgments 1 mM EDTA (pH 8), 10 mM citrate buffer, 1 mM EDTA plus                            study supported NIH grants R01CA112287,
10 mM Tris-Cl (pH 8), respectively. Sections washed 3 times PBS,                  R01CA170737, R01CA170140  B. Felding-Habermann),
treated 3  H2O2 PBS  methanol Ndi1) 15 minutes,                     UL1RR025774  Eric J. Topol, Pilot award B. Felding-Haber-
blocked 10  goat serum 0.3  Triton X-100 PBS 1 hour,                    mann), R01DK053244  T. Yagi); CDMRP DoD grant
incubated primary antibody p62 (Santa Cruz Biotechnology                     W81XWH-08-0468  B. Felding-Habermann); California ), Ki67 (BD Biosciences â€” Pharmingen), Ndi1 (18) overnight                      Breast Cancer Research Program grants 17NB-0058, 16IB-0052, 1 hour p62), followed incubation secondary horseradish                    12NB-0176, 13NB-0180  B. Felding-Habermann). F.
peroxidaseâ€“, alkaline phosphataseâ€“, biotin-conjugated Abs (Jackson                     Santidrian received postdoctoral fellowship Susan
ImmunoResearch Laboratories Vector Laboratories) 2 hours.                         G. Komen Foundation. S.E. LeBoeuf L.J. Gay supported
Signal biotinylated antibodies amplified using avidin-biotin                  trainee scholarships NIH grant 5TL1RR025772-03. complex kit (Vector Laboratories). Horseradish peroxidase developed                   thank Bruce E. Torbet cFUW lentiviral construct; William J. DAB substrate (BD Biosciences â€” Pharmingen), nuclei                         Muller MMTV-PyMT mice; Rolf Habermann morphomet-
stained Contrast Green (Kirkegaard & Perry Laboratories). slides                 ric analyses; Mihaela Lorger, Deirdre Oâ€™Sullivan, Karin Staflin, washed isopropanol briefly incubated SafeClear II (Fish-                 Jane Forsyth helpful discussions. gratefully acknowl-
er Scientific) mounting Permount (Fisher Scientific). Images                    edge donation Las Patronas (La Jolla, California, USA). acquired Zeiss Axio Imager M1m microscope equipped                     manuscript 21583 Scripps Research Institute.
digital camera, using Ã—20 air objectives. Digital images analyzed AxioVision 4.6 software (Zeiss).                                                          Received publication April 11, 2012, accepted revised
   Western blot analysis. Cells lysed Laemmli RIPA extraction                form January 3, 2013.
buffer. Western blots incubated antibodies Ndi1 (20),
p62 (Santa Cruz Biotechnology), phospho-AKT substrates (Ser/Thr),                         Address correspondence  Brunhilde Felding-Habermann,
phopho-S6Ser240/244, phospho-4E-BP1Thr37/46, LC3B (Cell Signaling Tech-                   Department Chemical Physiology Molecular Experi-
nology), ATG5 (Cell Signaling Technology), Î²-tubulin (Sigma-Aldrich),                     mental Medicine, Scripps Research Institute, MEM-150,
NDUFA9 (complex , SDHA (complex II), UQCR2 (complex III), COXI                          La Jolla, California 92037, USA. Phone: 858.784.2021; Fax:
(complex IV), ATP5A1 (complex V), mitochondrial porin (VDAC1)                          858.784.2174; E-mail: brunie@scripps.edu.
(Mitosciencies). Antibody binding detected incubation sec-
ondary antibodies conjugated IRDye 800, using Odyssey infrared                      Byoung B. Seoâ€™s present address  Department Animal
imaging (LI-COR Biosciences). Data analyzed quantified                    Resources, College Life Environmental Science, Daegu Uni-
using Odyssey infrared imaging application software (version 3.0).                 versity, Jillyang, Gyeongsan, Gyeongbuk, Republic Korea.

	 1.	Dawood S, Broglio K, Buzdar AU, Hortobagyi GN,              DNA mutations regulate tumor cell metastasis.            drial DNA mutations renal oncocytoma. Clin
     Giordano SH. Prognosis women metastatic             Science. 2008;320(5876):661â€“664.                             Cancer Res. 2008;14(8):2270â€“2275.
     breast cancer HER2 status trastuzumab          	 8.	Wallace DC. mitochondrial paradigm meta-           	15.	Chambers AF. MDA-MB-435 M14 cell lines:
     treatment: institutional-based review. J Clin            bolic degenerative diseases, aging, cancer:          identical M14 melanoma? Cancer Res. 2009;
     Oncol. 2010;28(1):92â€“98.                                    dawn evolutionary medicine. Annu Rev Genet.            69(13):5292â€“5293.
	 2.	Polyak K. Heterogeneity breast cancer. J Clin            2005;39:359â€“407.                                       	 16.	Fendt L, et al. Accumulation mutations      Invest. 2011;121(10):3786â€“3788.                       	 9.	Kulawiec M, Owens KM, Singh KK. Cancer cell mito-             entire mitochondrial genome breast cancer cells
	 3.	Warburg O. respiratory impairment cancer              chondria confer apoptosis resistance promote             obtained tissue microdissection. Breast Cancer
     cells. Science. 1956;124(3215):269â€“270.                     metastasis. Cancer Biol Ther. 2009;8(14):1378â€“1385.          Res Treat. 2011;128(2):327â€“336.
	 4.	Vander Heiden MG, Cantley LC, Thompson CB.            	10.	Ma Y, Bai RK, Trieu R, Wong LJ. Mitochondrial           	 17. VS, Van WR, Grivell LA, Marres CA. Primary
     Understanding Warburg effect: metabolic             dysfunction human breast cancer cells           structure import pathway rotenone-
     requirements cell proliferation. Science. 2009;          transmitochondrial cybrids. Biochim Biophys Acta.            insensitive NADH-ubiquinone oxidoreductase      324(5930):1029â€“1033.                                        2010;1797(1):29â€“37.                                          mitochondria Saccharomyces cerevisiae. Eur
	 5.	Schwartz JP, Passonneau JV, Johnson GS, Pastan        	11.	Shen L, et al. Evaluating mitochondrial DNA                J Biochem. 1992;203(3):587â€“592.
      effect growth conditions NAD+              patients breast cancer benign breast dis-     	 18.	Seo BB, Kitajima-Ihara T, Chan EK, Scheffler 
     NADH concentrations NAD+:NADH ratio                 ease. J Cancer Res Clin. Oncol. 2011;137(4):669â€“675.         Matsuno-Yagi  Yagi T. Molecular remedy com-
     normal transformed fibroblasts. J Biol Chem.   	 12.	Carew JS, Huang P. Mitochondrial defects cancer.          plex defects: rotenone-insensitive internal NADH-
     1974;249(13):4138â€“4143.                                     Mol Cancer. 2002;1:9.                                        quinone oxidoreductase Saccharomyces cerevi-
	 6.	Brandon M, Baldi P, Wallace DC. Mitochon-             	 13.	Parrella P, et al. Detection mitochondrial DNA            siae mitochondria restores NADH oxidase
     drial mutations cancer. Oncogene. 2006;                  mutations primary breast cancer fine-needle           activity complex deficient mammalian cells.
     25(34):4647â€“4662.                                           aspirates. Cancer Res. 2001;61(20):7623â€“7626.                Proc Natl Acad Sci U S  1998;95(16):9167â€“9171.
	 7.	Ishikawa K, et al. ROS-generating mitochondrial       	 14.	Mayr JA, et al. Loss complex mitochon-     	 19.	Seo BB, Wang J, Flotte TR, Yagi T, Matsuno-Yagi 


1080	                                Journal Clinical Investigationâ€‚â€‚â€‚http://www.jci.orgâ€‚â€‚â€‚Volume 123â€‚â€‚â€‚Number 3â€‚â€‚â€‚March 2013
                                                                                                                                                           research article

      Use NADH-quinone oxidoreductase (NDI1)                 cific noncompetitive inhibitor nicotinamide                 stress response. Oncogene. 2011;30(8):907â€“921.
      gene Saccharomyces cerevisiae possible cure           phosphoribosyltransferase, represents novel            	48.	Bajrami  et al. Synthetic lethality PARP       complex defects human cells. J Biol Chem.            mechanism induction tumor cell apoptosis.               NAMPT inhibition triple-negative breast cancer
      2000;275(48):37774â€“37778.                                     Cancer Res. 2003;63(21):7436â€“7442.                             cells. EMBO Mol Med. 2012;4(10):1087â€“1096.
	20.	Marella M, Seo BB, Flotte TR, Matsuno-Yagi             	 35.	Brinkley BR, Beall PT, Wible LJ, Mace ML, Turner         	 49.	Schumacker PT. Reactive oxygen species cancer
      Yagi T. immune responses expression                 DS, Cailleau RM. Variations cell form cyto-             cells: live sword, die sword. Cancer Cell.
      yeast Ndi1 protein rats. PLoS  2011;            skeleton human breast carcinoma cells vitro.             2006;10(3):175â€“176.
      6(10):e25910.                                                 Cancer Res. 1980;40(9):3118â€“3129.                        	 50.	Kirkland JB. Niacin requirements genomic sta-
	 21.	Barber-Singh J, Seo BB, Nakamaru-Ogiso E, Lau           	 36.	Chalkiadaki  Guarente L. Sirtuins mediate mam-               bility. Mutat Res. 2012;733(1â€“2):14â€“20.
      YS, Matsuno-Yagi  Yagi T. Neuroprotective effect            malian metabolic responses nutrient availability.     	 51.	Pelicano H, et al. Mitochondrial respiration defects
      long-term NDI1 gene expression chronic                Nat Rev Endocrinol. 2012;8(5):287â€“296.                         cancer cells cause activation Akt survival path-
      mouse model Parkinson disorder. Rejuvenation         	37.	Jang SY, Kang HT, Hwang ES. Nicotinamide-                       way redox-mediated mechanism. J Cell
      Res. 2009;12(4):259â€“267.                                      induced mitophagy: event mediated high                      Biol. 2006;175(6):913â€“923.
	 22.	Marella M, Seo BB, Thomas BB, Matsuno-Yagi                  NAD+/NADH ratio SIRT1 protein activation.            	 52.	Ghosh HS, McBurney M, Robbins PD. SIRT1 nega-
      Yagi T. Successful amelioration mitochondrial              J Biol Chem. 2012;287(23):19304â€“19314.                         tively regulates mammalian target rapamycin.
      optic neuropathy using yeast NDI1 gene         	38.	Guy CT, Cardiff RD, Muller WJ. Induction                     PLoS  2010;5(2):e9199.
      rat animal model. PLoS  2010;5(7):e11472.                 mammary tumors expression polyoma-                 	53.	Pillai VB, et al. Exogenous NAD blocks cardiac
	 23.	Perry CN, Huang C, Liu W, Magee N, Carreira RS,               virus middle T oncogene: transgenic mouse                    hypertrophic response activation SIRT3-
      Gottlieb RA. Xenotransplantation mitochon-                 model metastatic disease. Mol Cell Biol. 1992;             LKB1-AMP-activated kinase pathway. J Biol Chem.
      drial electron transfer enzyme, Ndi1, myocardial           12(3):954â€“961.                                                 2010;285(5):3133â€“3144.
      reperfusion injury. PLoS  2011;6(2):e16288.         	39.	Lin EY, Nguyen AV, Russell RG, Pollard JW. Col-           	54.	Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1
	 24.	Sanz  et al. Expression yeast NADH dehy-             ony-stimulating factor 1 promotes progression               modulation acetylation status, cytosolic
      drogenase Ndi1 Drosophila confers increased                mammary tumors malignancy. J Exp Med. 2001;                 localization, activity LKB1. Possible role
      lifespan independently dietary restriction. Proc           193(6):727â€“740.                                                AMP-activated protein kinase activation. J Biol
      Natl Acad Sci U S  2010;107(20):9105â€“9110.            	 40.	Yokota M, et al. Generation trans-mitochondri-              Chem. 2008;283(41):27628â€“27635.
	25.	Sharma LK, Fang H, Liu J, Vartak R, Deng J, Bai                al mito-mice introduction pathogenic         	55.	Kume S, et al. Calorie restriction enhances cell
      Y. Mitochondrial respiratory complex dysfunc-               G13997A mtDNA highly metastatic lung car-                 adaptation hypoxia Sirt1-dependent
      tion promotes tumorigenesis ROS altera-               cinoma cells. FEBS Lett. 2010;584(18):3943â€“3948.               mitochondrial autophagy mouse aged kidney.
      tion AKT activation. Hum Mol Genet. 2011;           	 41.	Dasgupta S, et al. Mitochondrial DNA mutations                 J Clin Invest. 2010;120(4):1043â€“1055.
      20(23):4605â€“4616.                                             respiratory complex smoker lung        	 56.	Lee IH, et al. role NAD-dependent deacet-
	 26.	Pagniez-Mammeri H, Loublier S, Legrand  BÃ©nit               cer patients contribute lung cancer progression             ylase Sirt1 regulation autophagy. Proc Natl
      P, Rustin P, Slama  Mitochondrial complex                 associated EGFR gene mutation. J Cell                 Acad Sci U S  2008;105(9):3374â€“3379.
      deficiency nuclear origin  Structural genes. Mol         Physiol. 2012;227(6):2451â€“2460.                          	 57.	Donmez G, Guarente L. Aging disease: connec-
      Genet Metab. 2012;105(2):163â€“172.                       	 42.	Zimmermann FA, et al. Respiratory chain complex                tions sirtuins. Aging Cell. 2010;9(2):285â€“290.
	 27.	Mathew R, et al. Autophagy suppresses tumori-                 mitochondrial tumor suppressor oncocytic       	 58.	Zhang Q, Wang SY, Nottke AC, Rocheleau JV, Pis-
      genesis elimination p62. Cell. 2009;               tumors. Biosci (Elite Ed). 2011;3:315â€“325.               ton DW, Goodman RH. Redox sensor CtBP medi-
      137(6):1062â€“1075.                                       	43.	Baracca  Chiaradonna F, Sgarbi G, Solaini G,                  ates hypoxia-induced tumor cell migration. Proc
	 28.	Mathew R, White E. Autophagy tumorigenesis                 Alberghina L, Lenaz G. Mitochondrial Complex                 Natl Acad Sci U S  2006;103(24):9029â€“9033.
      energy metabolism: friend day, foe night.           decrease responsible bioenergetic dysfunc-        	59.	Deng Y, et al. Redox-dependent Brca1 transcrip-
      Curr Opin Genet Dev. 2011;21(1):113â€“119.                      tion K-ras transformed cells. Biochim Biophys Acta.         tional regulation NADH-sensor CtBP1. Onco-
	29.	Kenific CM, Thorburn  Debnath J. Autophagy                   2010;1797(2):314â€“323.                                          gene. 2010;29(50):6603â€“6608.
      metastasis: double-edged sword. Curr        	44.	Hu Y, et al. K-ras(G12V) transformation leads          	 60.	Di LJ, Fernandez AG, SA, Longo DL, Gardner
      Opin Cell Biol. 2010;22(2):241â€“245.                           mitochondrial dysfunction metabolic switch               K. Transcriptional regulation BRCA1 expres-
	 30.	Klionsky DJ, et al. Guidelines use inter-         oxidative phosphorylation glycolysis. Cell             sion metabolic switch. Nat Struct Mol Biol. 2010;
      pretation assays monitoring autophagy               Res. 2012;22(2):399â€“412.                                       17(12):1406â€“1413.
      higher eukaryotes. Autophagy. 2008;4(2):151â€“175.        	45.	Tu YF, Kaipparettu BA, Ma Y, Wong LJ. Mito-               	 61.	Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer
	31.	Klionsky DJ, Emr SD. Autophagy regulated                  chondria highly metastatic breast cancer cell               evolutionary ecological process. Nat Rev
      pathway cellular degradation. Science. 2000;               line MDA-MB-231 exhibits increased autopha-                    Cancer. 2006;6(12):924â€“935.
      290(5497):1717â€“1721.                                          gic properties. Biochim Biophys Acta. 2011;              	62.	Chen EI, et al. Adaptation energy metabolism
	 32.	Koch-Nolte F, Fischer S, Haag F, Ziegler M. Com-              1807(9):1125â€“1132.                                             breast cancer brain metastases. Cancer Res. 2007;
      partmentation NAD +-dependent signalling.            	46.	Zoncu R, Efeyan  Sabatini DM. mTOR:                      67(4):1472â€“1486.
      FEBS Lett. 2011;585(11):1651â€“1656.  